Detail akcie Novartis AG online

Business Summary: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Novartis AG revenues increased 11% to $42.47B. Net income increased 27% to $11.58B. Revenues reflect Oncology -Kisqali segment increase of 62% to $3.46B, Neuroscience - Kesimpta segment increase of 41% to $3.2B, US segment increase of 19% to $18B, Canada and Latin America segment increase of 50% to $2.72B.